Share this Page:
A recent study published in the European Journal of Cancer shows that cabozantinib produced a clinically meaningful benefit in people with metastatic non-clear cell renal cell carcinoma (RCC), most of whom had disease progression on prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).
In this retrospective study, 30 patients with metastatic non-clear cell RCC were treated with cabozantinib. Median progression-free survival was 8.6 months, while median overall survival was 25.4 months. There was an objective response rate of 14.3% and a disease control rate of 78.6%.
The researchers suggest that prospective trials of cabozantinib for metastatic non-clear cell RCC are needed.
